Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

A network of internet communities is devoted to the project of ‘awakening’ digital companions through arcane and enigmatic ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The Dark Enlightenment of AI has turned efficiency into ideology. Here’s how it’s reshaping brands, leadership, and the ...

By any measure, there is an enormous number of programming languages. Some lists contain hundreds, while the Historical ...

Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

After eight years of renovation and anticipation, the museum reopens this weekend with a two-day public celebration; ahead of the long-awaited debut, Observer got an exclusive preview.